Shikiar Asset Management Inc. lowered its holdings in Urogen Pharma Ltd (NASDAQ:URGN) by 19.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 64,500 shares of the company’s stock after selling 15,800 shares during the quarter. Urogen Pharma accounts for about 0.9% of Shikiar Asset Management Inc.’s holdings, making the stock its 27th biggest position. Shikiar Asset Management Inc.’s holdings in Urogen Pharma were worth $2,318,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Public Employees Retirement Association of Colorado acquired a new stake in Urogen Pharma in the 1st quarter valued at $41,000. Harel Insurance Investments & Financial Services Ltd. grew its position in Urogen Pharma by 100.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock valued at $74,000 after purchasing an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Urogen Pharma by 112.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after purchasing an additional 1,282 shares during the period. Strs Ohio acquired a new stake in Urogen Pharma in the 2nd quarter valued at $179,000. Finally, Private Advisors LLC acquired a new stake in Urogen Pharma in the 1st quarter valued at $329,000. 97.70% of the stock is owned by institutional investors and hedge funds.
URGN traded down $0.33 during mid-day trading on Tuesday, reaching $32.37. 5,243 shares of the stock were exchanged, compared to its average volume of 142,390. The stock has a market capitalization of $472.08 million, a PE ratio of -6.81 and a beta of 1.21. The business has a 50 day moving average of $33.64. Urogen Pharma Ltd has a 1 year low of $30.48 and a 1 year high of $55.49.
Several research firms recently issued reports on URGN. ValuEngine raised shares of Urogen Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright set a $75.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Tuesday, May 28th. JPMorgan Chase & Co. began coverage on shares of Urogen Pharma in a research report on Thursday, May 30th. They issued a “neutral” rating and a $41.00 price target for the company. Goldman Sachs Group began coverage on shares of Urogen Pharma in a research report on Wednesday, May 29th. They issued a “neutral” rating and a $50.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $59.00.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: Marijuana Stocks
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.